Pathstone Holdings’s SAB Biotherapeutics SABS Stock Holding History

Pathstone Holdings’s Portfolio SABS Stock Details SABS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$161K	Buy	50,935 +285	+0.6%	+$1.04K	﹤0.01%	2319
2026 Q2	$198K	Hold	50,650	–	–	﹤0.01%	2237
2026 Q1	$194K	Hold	50,650	–	–	﹤0.01%	2114
2025 Q4	$189K	Hold	50,650	–	–	﹤0.01%	2117
2025 Q3	$102K	Hold	50,650	–	–	﹤0.01%	2269
2025 Q2	$88.9K	Hold	50,650	–	–	﹤0.01%	2128
2025 Q1	$68.9K	Hold	50,650	–	–	﹤0.01%	2169
2024 Q4	$192K	Hold	50,650	–	–	﹤0.01%	2179
2024 Q3	$137K	Hold	50,650	–	–	﹤0.01%	2226
2024 Q2	$157K	Hold	50,650	–	–	﹤0.01%	2190
2024 Q1	$230K	Sell	50,650 -1	-0%	-$6	﹤0.01%	2073
2023 Q4	$348K	Buy	+50,651	New	+$425K	﹤0.01%	1726

Other funds holding SABS

Vivo Capital Palo Alto, California $909M AUM 385.65% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Spruce Street Capital New York $629M AUM 210.46% 1-Year Est. Return

Sanofi Paris, France $630M AUM 104.49% 1-Year Est. Return

Affinity Asset Advisors New York $2.46B AUM 196.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Propel Bio Management Los Angeles, California $189M AUM 71.31% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $60.6B AUM 33.98% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Pathstone Holdings's SABS Position: Q3 2026 in Review

Pathstone Holdings increased its SAB Biotherapeutics (SABS) stake by 0.56% in Q3 2026, buying an estimated $1.04K and bringing the position to 50,935 shares worth $161K. The position accounts for ﹤0.01% of the portfolio, ranked #2319.

Pathstone Holdings first reported a position in SABS in Q4 2023 and has held it in 12 quarters since. The position peaked at $348K in Q4 2023. 61 funds tracked by Wall St. Rank hold SABS as of Q3 2026.

Pathstone Holdings held 50,935 shares of SAB Biotherapeutics worth $161K as of Q3 2026.
Pathstone Holdings bought 285 SAB Biotherapeutics shares in Q3 2026, an estimated $1.04K.
SAB Biotherapeutics made up ﹤0.01% of Pathstone Holdings's portfolio in Q3 2026, its #2319 holding.
Pathstone Holdings first reported a position in SAB Biotherapeutics in Q4 2023 and has held it in 12 quarters since.
Pathstone Holdings's SAB Biotherapeutics position peaked at $348K in Q4 2023.
61 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q3 2026.

Based on Pathstone Holdings's 13F filing for Q3 2026, filed 13 Nov 2026.